Lantheus_Logo.png
Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
12 févr. 2025 08h00 HE | Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday,...
Lantheus_Logo.png
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
05 févr. 2025 08h30 HE | Lantheus Holdings, Inc.
Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being...
Lantheus_Logo.png
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
30 janv. 2025 08h30 HE | Lantheus Holdings, Inc.
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus_Logo.png
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
28 janv. 2025 06h00 HE | Lantheus Holdings, Inc.
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset,...
Lantheus_Logo.png
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market
13 janv. 2025 00h05 HE | Lantheus Holdings, Inc.
Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’...
Lantheus_Logo.png
Lantheus Announces Share Repurchase Program
20 nov. 2024 01h00 HE | Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians...
Lantheus_Logo.png
Lantheus to Present at the Jefferies London Healthcare Conference
13 nov. 2024 08h30 HE | Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus_Logo.png
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
11 nov. 2024 07h39 HE | Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling...
Lantheus_Logo.png
Lantheus Reports Third Quarter 2024 Financial Results
06 nov. 2024 07h00 HE | Lantheus Holdings, Inc.
Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted...
Lantheus_Logo.png
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
04 nov. 2024 07h30 HE | Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...